Lung (includes NSCLC, SCLC, Mesothelioma)

Active Surveillance Of Lung Subsolid Nodules Reduces Unnecessary Surgery And Overtreatment

(IASLC) July 16, 2018 - Subsolid nodules (SSN) can be considered a biomarker of lung cancer risk and should be managed with long-term active surveillance. Conservative management of SSN will reduce unnecessary surgery and overtreatment in patients with multiple comorbidities and aggressive lung cancer arising from lung sites other than the SSN.

read press release

Immunotherapies in Early-Stage Lung Cancer Show Promising Effects

(Weill Cornell Medicine) July 12, 2018 - Treating early-stage lung cancers with drugs that unleash the immune system’s ability to attack malignant cells may hinder tumor growth and improve overall survival, according to new research by Weill Cornell Medicine and NewYork-Presbyterian investigators.

read article

Study Shows Biomarker Panel Boosts Lung Cancer Risk Assessment For Smokers

(MD Anderson) July 12, 2018 - A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smokers, an international research team reports in JAMA Oncology.

read press release

Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors

(Seattle Genetics) July 12, 2018 - Seattle Genetics, Inc. today announced dosing of the first patient in the phase 2 innovaTV 207 clinical trial evaluating the activity, safety and tolerability of tisotumab vedotin as monotherapy in selected solid tumors with high Tissue Factor expression.

read corporate press release

Applying 'Already Done' Science to Cancer Control

(MedPage Today) July 11, 2018 - A fourth of cancer deaths in the U.S. would not occur if everyone had the same cancer mortality as college-educated Americans, authors of an American Cancer Society (ACS) study reported.

read article (free registration required)

Health Canada Approves Tagrisso® (osimertinib) as First-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer

(The Business Journals) July 12, 2018 - AstraZeneca Canada today announced that Health Canada has approved Tagrisso® (osimertinib) for the first-line treatment of patients with locally advanced (not amenable to curative therapies), or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations).

read article

Brain Metastases Common And Difficult To Treat In ROS1 Lung Cancer

(UCCC/Colorado Cancer Blogs) July 10, 2018 - Increasingly, doctors are treating lung cancer based on the genetic rearrangements driving the disease. For example, cancers that are driven by changes in the genes ALK, EGFR, and ROS1 can now all be paired with drugs that target these specific changes.

read article

Colgate-Palmolive Settles Talc Cancer Case Ahead Of Trial

(Reuters) July 10, 2018 - Colgate-Palmolive on Monday settled after eight days of jury selection a lawsuit brought by a California man who alleged his use of talcum powder made by the company’s predecessor exposed him to asbestos and caused his mesothelioma.

read article

First Opinion: Opioid Stigma Is Keeping Many Cancer Patients From Getting The Pain Control They Need

(STAT) July 6, 2018 - History is repeating itself. Twenty years ago, a pain management crisis existed. As many as 70 percent of cancer patients in treatment at that time, or in end-of-life care, experienced unalleviated pain.

read article

Hitting Cancer Early: Astrazeneca's Bid To Outmaneuver Rivals

(Reuters) July 6, 2018 - AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit.

read article

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy as First-Line Treatment for Metastatic Squamous Non-Small Cell Lung Cancer

(Merck) July 2, 2018 - Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 expression.

read corporate press release

FDA Grants Priority Review to Frontline Keytruda Combination in Metastatic NSCLC

(Curetoday.com) July 2, 2018 - The Food and Drug Administration (FDA) granted a priority review to Keytruda (pembrolizumab) in combination with chemotherapy as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 expression, according to Merck, the manufacturer of the anti-PD-1 agent.

read article

AstraZeneca Cancer Drugs Approved In Japan

(Pharmaphorum.com [UK]) July 2, 2018 - AstraZeneca secured a fast approval of lung and breast cancer drugs with usually sluggish Japanese regulators, just months after scoring similar approvals in the West.

read article

AstraZeneca Wins Speedy Approvals For Cancer Drugs In Japan

(Reuters) July 2, 2018 - AstraZeneca has won rapid regulatory approval for new uses of two of its important cancer drugs in Japan, less than six months after the first global approvals in Western markets.

read article

OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi®

(NASDAQ) July 2, 2018 - OSE Immunotherapeutics SA received approval from the Independent Data Monitoring Committee (IDMC) to continue Atalante 1, the Company's international pivotal Phase 3 clinical study of Tedopi® for the treatment of Non-Small Cell Lung Cancer (NSCLC) following immune checkpoint inhibitor treatment.

read article

Compugen Shares Surge 12% Premarket After FDA Lifts Clinical Hold On Cancer Treatment

(MarketWatch) July 2, 2018 - Compugen Ltd. shares climbed 12% in premarket trade Monday, after the Israeli biotech said the U.S. Food and Drug Administration has lifted a clinical hold on its investigational new drug (IND) application for COM701, an immuno-oncology therapeutic antibody.

read article

VATS Proves Mettle in Early-Stage NSCLC

(MedPage Today) June 28, 2018 - Patients with stage I non-small cell lung cancer (NSCLC) had better 4-year survival if they underwent video-assisted minimally invasive surgery instead of open surgery, a retrospective analysis of 10,597 patients showed.

read article (free registration required)

Geriatric Assessments Could Fine-Tune Cancer Care For Older Adults

(Kaiser Health News) June 28, 2018 - In a move to improve cancer care for older adults, the American Society of Clinical Oncology is recommending that all patients age 65 and older receive a geriatric assessment when considering or undergoing chemotherapy.

read article

Mutation-counting Blood Test Could Predict If Cutting-Edge Immunotherapies Can Beat A Cancer

(Science Magazine) June 27, 2018 - A recently unveiled blood test for this so-called tumor mutational burden (TMB) could help make it a practical tool for guiding cancer treatment.

read article

NICE Backs Roche’s Alecensa

(PharmaTimes [UK]) June 28, 2018 - Roche’s Alecensa has won NICE backing as a treatment for a rare type of lung cancer, over-turning a prior decision to reject NHS funding for the drug.

read article
Next Page